113 related articles for article (PubMed ID: 33967149)
1. [Improvement in platelet count and bleeding symptom during treatment with eltrombopag in a patient with X-linked thrombocytopenia].
Moriyama M; Nishikawa T; Nakamura T; Abematsu T; Nakagawa S; Kodama Y; Okamoto Y; Iwamoto J; Kawano Y
Rinsho Ketsueki; 2021; 62(4):257-261. PubMed ID: 33967149
[TBL] [Abstract][Full Text] [Related]
2. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
Gerrits AJ; Leven EA; Frelinger AL; Brigstocke SL; Berny-Lang MA; Mitchell WB; Revel-Vilk S; Tamary H; Carmichael SL; Barnard MR; Michelson AD; Bussel JB
Blood; 2015 Sep; 126(11):1367-78. PubMed ID: 26224646
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
Gabelli M; Marzollo A; Notarangelo LD; Basso G; Putti MC
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643468
[TBL] [Abstract][Full Text] [Related]
4. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J; Larratt L; Tinmouth A; Amini S; Schipperus M; Lim W; Vishnu P; Warner M; Carruthers J; Li N; Lane S; Kelton JG
Lancet Haematol; 2020 Sep; 7(9):e640-e648. PubMed ID: 32853584
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.
Zaninetti C; Gresele P; Bertomoro A; Klersy C; De Candia E; Veneri D; Barozzi S; Fierro T; Alberelli MA; Musella V; Noris P; Fabris F; Balduini CL; Pecci A
Haematologica; 2020 Mar; 105(3):820-828. PubMed ID: 31273088
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.
Pecci A; Gresele P; Klersy C; Savoia A; Noris P; Fierro T; Bozzi V; Mezzasoma AM; Melazzini F; Balduini CL
Blood; 2010 Dec; 116(26):5832-7. PubMed ID: 20844233
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
10. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.
Suzuki N; Hiraga J; Hariyama Y; Takagi Y; Ohashi H; Kishigami Y; Oguchi H; Kagami Y
Int J Hematol; 2018 Jul; 108(1):109-111. PubMed ID: 29188582
[TBL] [Abstract][Full Text] [Related]
11. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia.
Favier R; Feriel J; Favier M; Denoyelle F; Martignetti JA
Pediatrics; 2013 Sep; 132(3):e793-5. PubMed ID: 23940247
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Ahmed S; Bashir Q; Bassett R; Poon MC; Valdez B; Konoplev S; Alousi AM; Andersson BS; Ciurea S; Hosing C; Jones R; Kebriaei P; Khouri I; Kim S; Nieto Y; Olson A; Oran B; Parmar S; Qazilbash MH; Rezvani K; Shah N; Shpall EJ; Champlin R; Popat U
Transplant Cell Ther; 2021 May; 27(5):430.e1-430.e7. PubMed ID: 33965187
[TBL] [Abstract][Full Text] [Related]
15. Intermittent low platelet counts hampering diagnosis of X-linked thrombocytopenia in children: report of two unrelated cases and a novel mutation in the gene coding for the Wiskott-Aldrich syndrome protein.
Medina SS; Siqueira LH; Colella MP; Yamaguti-Hayakawa GG; Duarte BKL; Dos Santos Vilela MM; Ozelo MC
BMC Pediatr; 2017 Jun; 17(1):151. PubMed ID: 28641574
[TBL] [Abstract][Full Text] [Related]
16. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag.
Chang H; Shih LY
Tumori; 2015 Apr; 101(2):e49-50. PubMed ID: 25702666
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
